Brevan Howard offered $25 million 'refund right' for its Berachain investment: Unchained
Quick Take Brevan Howard’s 2024 investment in Berachain reportedly came with a refund stipulation active for one year following the BERA token launch, according to documents published by Unchained. The firm’s Nova Digital subsidiary co-led Berachain’s $69 million Series B funding round at a $1.5 billion valuation.
Brevan Howard’s venture capital bet on Berachain allegedly came with near-zero risk, according to a new report by Jack Kubinec, writing for Unchained . Documents published on Monday show that Berachain granted Nova Digital — a crypto-focused Brevan subsidiary — a year-long refund right on its $25 million Series B investment.
In other words, Brevan could potentially recoup its investment in Berachain’s Feb. 6 token generation event after co-leading the project’s $69 million funding round at a $1.5 billion valuation. The firm reportedly has until Feb. 6, 2026, to exercise this right.
"The refund clause means that, unlike a traditional venture investment, Brevan's fund didn’t take on any risk to its principal. If Berachain's BERA token performs well, the fund will reap the rewards. If BERA flops, the fund can ask for its money back," Kubinec wrote.
BERA, trading at around $1, is down about 67% from Brevan’s investment price of $3 per token. The token has a current fully diluted valuation of $536.7 million, according to The Block’s price page .
That Series B was co-led with Framework Ventures, with participation from Arrington Capital, Hack VC, Polychain, and Tribe Capital. Berachain also raised a $42 million Series A in 2023. It is unclear if other investors also received refund rights.
According to a side letter signed by Berachain Foundation General Counsel Jonathan Ip and Nova Director Carol Reynolds, Nova may request "some or all" of its investment as part of a simple agreement for future tokens (SAFT) deal. To activate the arrangement, Nova was required to deposit $5 million into Berachain within 30 days of the TGE.
Of note, Nova operations were led by Kevin Hu, a BlackRock and Dragonfly Capital veteran who personally invested in Berachain's seed round. Brevan acquired the Nova Digital Master Opportunities Fund from venture firm Dragonfly in 2023.
Berachain, an Ethereum-compatible Layer 1 built using the Cosmos SDK, was one of the most anticipated blockchain launches of 2025. The protocol was born out of a 2021 NFT series called "Bong Bears" and quickly gained a cult-like following.
The Block reached out to Berachain and Brevan Howard Digital for comment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
